Topic

Blue Cross Blue Shield (BCBS Association)

A collection of 1072 issues

Florida Blue Cross Blue Shield Coverage for Oxlumo (Lumasiran): Complete Prior Authorization and Appeals Guide 2025

Answer Box: Getting Oxlumo Covered by Florida Blue Cross Blue Shield Florida Blue requires prior authorization for Oxlumo (lumasiran) with strict medical necessity criteria: confirmed PH1 diagnosis via genetic testing, elevated baseline urinary/plasma oxalate levels, specialist prescriber, and pyridoxine trial (unless contraindicated). Fastest path: Have your nephrologist submit PA
7 min read

How to Get Pomalyst (Pomalidomide) Covered by Blue Cross Blue Shield in Georgia: Complete Prior Authorization Guide

Answer Box: Getting Pomalyst Covered by BCBS Georgia Pomalyst (pomalidomide) requires prior authorization from Blue Cross Blue Shield Georgia (Anthem) and must be filled through their specialty pharmacy networks (CarelonRx or BioPlus). To get approved: 1) Your oncologist submits a PA request documenting prior lenalidomide and proteasome inhibitor failure, 2)
5 min read

Do You Qualify for Luxturna (Voretigene Neparvovec-rzyl) Coverage by Blue Cross Blue Shield in Texas? Decision Tree & Appeals Guide

Answer Box: Getting Luxturna Covered in Texas Yes, Luxturna (voretigene neparvovec-rzyl) can be covered by Blue Cross Blue Shield of Texas for patients with confirmed biallelic RPE65 mutations and sufficient retinal viability. The fastest path: (1) Confirm genetic testing shows biallelic RPE65 pathogenic variants, (2) Submit prior authorization through BCBSTX
5 min read

How Long Does It Take to Get Somatuline Depot (lanreotide) Approved by Blue Cross Blue Shield in Virginia? Complete Timeline & Appeals Guide

Answer Box: Getting Somatuline Depot (lanreotide) approved by Blue Cross Blue Shield in Virginia typically takes 5-10 business days for standard prior authorization, or 72 hours for expedited cases. Your fastest path: Have your endocrinologist/oncologist submit complete documentation including diagnosis confirmation, prior octreotide trial details, and medical necessity justification
6 min read